Extraordinary General Meeting held in Nordic Nanovector ASA
Reference is made to the notice of Extraordinary General Meeting distributed to the shareholders of Nordic Nanovector ASA (the “Company”) on 4 November 2014.
The proposals set out in the notice of the Extraordinary General Meeting have today been resolved. This included, among other things, the conversion of the Company into a public limited company, Board and Nomination Committee elections and remuneration, instructions for the Nomination Committee and amendments to the Company’s articles of association.
Pursuant to the resolutions resolved in the General Meeting, the Company’s Board of Director is composed of the following persons:
• Ludvik Sandnes (Chairman)
• Roy H. Larsen
• Alexandra Morris
• Hilde Steineger
• Per Samuelsson
The General Meeting also resolved to increase the share capital by up to NOK 3,450 by the issuance of maximum 17,259 new shares in a share capital increase towards the Board Members who choose to receive remuneration in the form of shares to be subscribed to for their nominal value and which, based on a market price of NOK 30, have a value that correspond to the remuneration of the Board member resolved by the General Meeting.
The minutes of the Extraordinary General meeting is attached to this press release.
INFORMATION
Luigi Costa
Chief Executive Officer
Cell: (+41) 79 12 48 601
E-mail: lcosta@nordicnanovector.com
Tone Kvåle
Chief Financial Officer
Cell: (+47) 91 51 95 76
E-mail: tkvale@nordicnanovector.com
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
